BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cha SE, Kujawski M, J Yazaki P, Brown C, Shively JE. Tumor regression and immunity in combination therapy with anti-CEA chimeric antigen receptor T cells and anti-CEA-IL2 immunocytokine. Oncoimmunology 2021;10:1899469. [PMID: 33796409 DOI: 10.1080/2162402X.2021.1899469] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
Number Citing Articles
1 Shaw TI, Zhao B, Li Y, Wang H, Wang L, Manley B, Stewart PA, Karolak A. Multi-omics approach to identifying isoform variants as therapeutic targets in cancer patients. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.1051487] [Reference Citation Analysis]
2 Dai Z, Fu J, Peng X, Tang D, Song J. Intestinal Microbiota: The Driving Force behind Advances in Cancer Immunotherapy. Cancers (Basel) 2022;14:4796. [PMID: 36230724 DOI: 10.3390/cancers14194796] [Reference Citation Analysis]
3 Rao A, Stewart A, Eljalby M, Ramakrishnan P, Anderson LD, Awan FT, Chandra A, Vallabhaneni S, Zhang K, Zaha VG. Cardiovascular disease and chimeric antigen receptor cellular therapy. Front Cardiovasc Med 2022;9. [DOI: 10.3389/fcvm.2022.932347] [Reference Citation Analysis]
4 Bozorgi A, Bozorgi M, Khazaei M. Immunotherapy and immunoengineering for breast cancer; a comprehensive insight into CAR-T cell therapy advancements, challenges and prospects. Cell Oncol (Dordr) 2022. [PMID: 35943716 DOI: 10.1007/s13402-022-00700-w] [Reference Citation Analysis]
5 Williams L, Dery KJ, Lee WH, Li H, Shively JE, Kujawski M. Isolation and expansion of murine γδ T cells from mouse splenocytes. J Immunol Methods 2022;508:113322. [PMID: 35843266 DOI: 10.1016/j.jim.2022.113322] [Reference Citation Analysis]
6 Chen L, Chen F, Niu H, Li J, Pu Y, Yang C, Wang Y, Huang R, Li K, Lei Y, Huang Y. Chimeric Antigen Receptor (CAR)-T Cell Immunotherapy Against Thoracic Malignancies: Challenges and Opportunities. Front Immunol 2022;13:871661. [DOI: 10.3389/fimmu.2022.871661] [Reference Citation Analysis]
7 Laureano RS, Sprooten J, Vanmeerbeerk I, Borras DM, Govaerts J, Naulaerts S, Berneman ZN, Beuselinck B, Bol KF, Borst J, Coosemans A, Datsi A, Fučíková J, Kinget L, Neyns B, Schreibelt G, Smits E, Sorg RV, Spisek R, Thielemans K, Tuyaerts S, De Vleeschouwer S, de Vries IJM, Xiao Y, Garg AD. Trial watch: Dendritic cell (DC)-based immunotherapy for cancer. OncoImmunology 2022;11:2096363. [DOI: 10.1080/2162402x.2022.2096363] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
8 Mohajershojai T, Jha P, Boström A, Frejd FY, Yazaki PJ, Nestor M. In Vitro Characterization of 177Lu-DOTA-M5A Anti-Carcinoembryonic Antigen Humanized Antibody and HSP90 Inhibition for Potentiated Radioimmunotherapy of Colorectal Cancer. Front Oncol 2022;12:849338. [PMID: 35433442 DOI: 10.3389/fonc.2022.849338] [Reference Citation Analysis]
9 Marofi F, Achmad H, Bokov D, Abdelbasset WK, Alsadoon Z, Chupradit S, Suksatan W, Shariatzadeh S, Hasanpoor Z, Yazdanifar M, Shomali N, Khiavi FM. Hurdles to breakthrough in CAR T cell therapy of solid tumors. Stem Cell Res Ther 2022;13:140. [PMID: 35365241 DOI: 10.1186/s13287-022-02819-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
10 Akbari P, Katsarou A, Daghighian R, van Mil LW, Huijbers EJ, Griffioen AW, van Beijnum JR. Directing CAR T cells towards the tumor vasculature for the treatment of solid tumors. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 2022. [DOI: 10.1016/j.bbcan.2022.188701] [Reference Citation Analysis]
11 Kujawski M, Li L, Li H, Yazaki PJ, Swiderski P, Shively JE. T-cell surface generation of dual bivalent, bispecific T-cell engaging, RNA duplex cross-linked antibodies (dbBiTERs) for re-directed tumor cell lysis. Biotechnol J 2021;:e2100389. [PMID: 34773368 DOI: 10.1002/biot.202100389] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Silver AB, Leonard EK, Gould JR, Spangler JB. Engineered antibody fusion proteins for targeted disease therapy. Trends Pharmacol Sci 2021;42:1064-81. [PMID: 34706833 DOI: 10.1016/j.tips.2021.09.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
13 Zimmermannova O, Caiado I, Ferreira AG, Pereira CF. Cell Fate Reprogramming in the Era of Cancer Immunotherapy. Front Immunol 2021;12:714822. [PMID: 34367185 DOI: 10.3389/fimmu.2021.714822] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]